TABLE 2.
Baseline characteristics for patients by number of prior sinus surgeries
| Characteristic |
No surgery (n = 265) |
≥1 surgery (n = 459) |
1 surgery (n = 254) |
2 surgeries (n = 94) |
≥3 surgeries (n = 111) |
Overall p a |
|---|---|---|---|---|---|---|
| Age (years), mean ± SD | 51.4 ± 13.2 | 51.4 ± 12.6 | 52.3 ± 12.6 | 49.5 ± 13.2 | 50.9 ± 11.9 | 0.32 |
| Male, n (%) | 169 (63.8) | 268 (58.4) | 148 (58.3) | 50 (53.2) | 70 (63.1) | 0.25 |
| BMI (kg/m2), mean ± SD | 28.50 ± 5.73 | 27.60 ± 5.30 | 26.95 ± 4.87 | 27.87 ± 5.38 | 28.87 ± 5.93 | 0.004 |
| Time since first diagnosis of NP (years), mean ± SD | 5.53 ± 6.02 | 14.20 ± 9.62 | 12.29 ± 9.48 | 14.60 ± 8.73 | 18.37 ± 9.42 | <0.001 |
| Age at onset of nasal polyposis (years), mean ± SD | 45.98 ± 13.01 | 37.23 ± 13.18 | 40.02 ± 13.24 | 35.00 ± 12.19 | 32.60 ± 12.27 | <0.001 |
| Asthma/NSAID‐ERD from medical history, n (%) | 129 (48.7) | 322 (70.2) | 171 (67.3) | 66 (70.2) | 85 (76.6) | <0.001 |
| SCS use within 2 years, n (%) | 246 (92.8) | 292 (63.6) | 160 (63.0) | 57 (60.6) | 75 (67.6) | <0.001 |
| Time since last surgery (years), mean ± SD | — | 7.16 ± 6.44 | 8.12 ± 7.40 | 6.50 ± 4.80 | 5.50 ± 4.69 | 0.004 |
| Time since last surgery category, n (%)b | ||||||
| <3 years | — | 136 (29.7) | 70 (27.7) | 24 (25.5) | 42 (37.8) | |
| ≥3 and < 5 years | — | 81 (17.7) | 41 (16.2) | 19 (20.2) | 21 (18.9) | |
| ≥5 and < 10 years | — | 133 (29.0) | 70 (27.7) | 28 (29.8) | 35 (31.5) | |
| ≥10 years | — | 108 (23.6) | 72 (28.5) | 23 (24.5) | 13 (11.7) | |
| Assessment scores, mean ± SD | ||||||
| NPS (0–8) | 6.15 ± 1.20 | 5.86 ± 1.26 | 5.96 ± 1.20 | 5.62 ± 1.31 | 5.83 ± 1.35 | 0.005 |
| NC score, 0–3 | 2.33 ± 0.60 | 2.44 ± 0.56 | 2.44 ± 0.55 | 2.33 ± 0.60 | 2.54 ± 0.54 | 0.015 |
| LMK score, 0–24 | 17.15 ± 3.92 | 19.07 ± 3.97 | 18.57 ± 4.23 | 19.34 ± 3.50 | 19.95 ± 3.59 | <0.001 |
| UPSIT score, 0–40 | 16.02 ± 8.93 | 12.80 ± 7.52 | 12.87 ± 7.82 | 12.97 ± 7.89 | 12.49 ± 6.48 | <0.001 |
| Loss of smell score (0–3) | 2.65 ± 0.54 | 2.79 ± 0.52 | 2.76 ± 0.56 | 2.81 ± 0.43 | 2.83 ± 0.50 | <0.001 |
| SNOT‐22 total score (0–110) | 49.72 ± 21.44 | 51.63 ± 20.19 | 51.49 ± 20.60 | 51.97 ± 20.77 | 51.68 ± 18.89 | 0.69 |
| VAS for EQ‐5D (0–100) | 65.56 ± 22.15 | 65.37 ± 19.34 | 65.74 ± 18.47 | 64.03 ± 20.73 | 65.61 ± 20.23 | 0.82 |
| Biomarkers, mean ± SD | ||||||
| Blood eosinophils (1 × 109/L) | 0.37 ± 0.31 | 0.47 ± 0.36 | 0.47 ± 0.37 | 0.43 ± 0.32 | 0.50 ± 0.36 | <0.001 |
| Total IgE (IU/mL) | 241.22 ± 308.35 | 222.31 ± 323.75 | 239.02 ± 350.90 | 187.99 ± 297.47 | 213.07 ± 276.39 | 0.05 |
| Periostin (ng/mL) | 104.96 ± 40.67 | 116.65 ± 52.43 | 118.04 ± 51.15 | 109.83 ± 45.61 | 119.21 ± 60.16 | 0.04 |
| TARC (pg/mL) | 351.19 ± 243.42 | 361.32 ± 256.44 | 362.89 ± 254.80 | 345.58 ± 195.63 | 371.22 ± 303.76 | 0.78 |
aChi‐square test for qualitative parameters, Kruskal‐Wallis test for quantitative parameters; to compare if there was a difference between at least 1 subgroups among patients with no surgery (except for time since last surgery), 1, 2, or ≥3 surgeries.
bData for time since last surgery were missing for 1 patient.
BMI = body mass index; EQ‐5D = European Quality of Life‐5 Dimensions; IgE = immunoglobulin E; LMK = Lund‐Mackay; NC = nasal congestion; NPS = nasal polyp score; NSAID‐ERD = nonsteroidal anti‐inflammatory drug‐exacerbated respiratory tract disease; SCS = systemic corticosteroid; SD = standard deviation; SNOT‐22 = 22‐item Sino‐Nasal Outcome Test; TARC = thymus and activation‐regulated chemokine; UPSIT = University of Pennsylvania Smell Identification Test; VAS = visual analogue scale.